



30 August 2022

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender (ITT) dated 2 November 2020, and 2021/22 ITT dated 1 November 2021.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of September 2022 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Midodrine ¹	Tab 2.5 mg; 100 tablet blister pack	\$53.00	\$38.23	Midodrine Medsurge (Medsurge)	1 March 2023	1 August 2023	Gutron (Douglas)
Midodrine ¹	Tab 5 mg; 100 tablet blister pack	\$79.00	\$59.98	Midodrine Medsurge (Medsurge)	1 March 2023	1 August 2023	Gutron (Douglas)
¹ Brand Switch Fee of \$4.50 is payable for this product from 1 August 2023 to 31 October 2023.							

Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule

2. *Tenders awarded to currently listed pharmaceuticals where no brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Midodrine	Tab 2.5 mg; 100 tablet blister pack	\$38.23	Midodrine Medsurge (Medsurge)	5%	1 March 2023	1 August 2023
Midodrine	Tab 5 mg; 100 tablet blister pack	\$59.98	Midodrine Medsurge (Medsurge)	5%	1 March 2023	1 August 2023

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to Pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablet blister pack ²	\$2.18 (per 84) \$6.45 (per 112)	\$1.50	Lo-Oralcon 20 ED (Viatris)	1 March 2023	1 August 2023	Microgynon 20 ED (Bayer) Femme-Tab ED (AFT)
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablet blister pack ²	\$1.77 (per 84) \$6.45 (per 112)	\$1.50	Oralcon 30 ED (Viatris)	1 March 2023	1 August 2023	Levlen ED (Bayer) Femme-Tab ED (AFT)
Ondansetron	Tab 4 mg; 50 tablet blister pack	\$2.68	\$2.27	Periset (Miro)	1 March 2023	1 August 2023	Onrex (Rex Medical)
Ondansetron	Tab 8 mg; 50 tablet blister pack	\$4.57	\$4.10	Periset (Miro)	1 March 2023	1 August 2023	Onrex (Rex Medical)
Posaconazole	Oral liq 40 mg per ml; 105 ml bottle OP	\$761.13	\$342.51	Devatis (Devatis)	1 December 2022	1 May 2023	Noxafil (MSD)
² The PSO quantity for this product will be amended from 112 to 84 tablets from 1 August 2023							

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

4. Tenders awarded to Pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablet blister pack	\$2.18	\$1.50	Lo-Oralcon 20 ED (Viatris)	5%	1 March 2023	1 August 2023	Microgynon 20 ED (Bayer)
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablet blister pack	\$1.77	\$1.50	Oralcon 30 ED (Viatris)	5%	1 March 2023	1 August 2023	Levlen ED (Bayer)
Ondansetron	Tab 4 mg; 50 tablet blister pack	\$2.68	\$2.27	Periset (Miro)	5%	1 March 2023	1 August 2023	Onrex (Rex Medical)
Ondansetron	Tab 8 mg; 50 tablet blister pack	\$4.57	\$4.10	Periset (Miro)	5%	1 March 2023	1 August 2023	Onrex (Rex Medical)
Posaconazole	Oral liq 40 mg per ml; 105 ml bottle	\$761.13	\$342.51	Devatis (Devatis)	5%	1 December 2022	1 May 2023	Noxafil (MSD)
Voriconazole	Inj 200 mg vial; 1 vial pack	\$44.00	\$19.85	AFT (AFT)	5%	1 March 2023	1 August 2023	Neo Health (Neo Health)

Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021

2021/22 Invitation to Tender

Chemical name	Line item
Risperidone	Inj 25 mg
Risperidone	Inj 37.5 mg
Risperidone	Inj 50 mg

For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.